Evolving Mutations in Metastatic Breast Cancer
Utthara Nayar, Ph.D.
April 16, 2018

Save as Favorite
Sign in to receive recommendations (Learn more)
Nayar utthara

Dr. Utthara Nayar is a research fellow in medicine at the Dana-Farber Cancer Institute, the Harvard Medical School, and the Broad Institute of MIT and Harvard. A cancer biologist, her broad research focuses on the interface of basic biology, targeted medicines, and drug resistance. At the 2018 American Association for Cancer Research Annual Meeting, she presented research looking at how acquired HER2 mutations can make some metastatic hormone-receptor-positive breast cancers resistant to hormonal therapy.

Listen to the podcast to hear Dr. Nayar explain:

  • the number of metastatic hormone-receptor-positive breast cancers that become resistant to hormonal therapy
  • what whole exome sequencing is and why she and her colleagues used it in this study
  • the possibility that genetic sequencing of cancers could be an ongoing part of treatment at some point in the future

Running time: 15:08

Lilly.podcastsupportrecognition

Show Full Transcript

Coming soon.

Hide Transcript


Was this article helpful? Yes / No

Supportpeopleyellow banner mini
Back to Top